Yu Nee Lee1, Francesco Frugoni1, Kerry Dobbs1, Jolan E Walter2, Silvia Giliani3, Andrew R Gennery4, Waleed Al-Herz5, Elie Haddad6, Francoise LeDeist6, Jack H Bleesing7, Lauren A Henderson1, Sung-Yun Pai8, Robert P Nelson9, Dalia H El-Ghoneimy10, Reem A El-Feky10, Shereen M Reda10, Elham Hossny10, Pere Soler-Palacin11, Ramsay L Fuleihan12, Niraj C Patel13, Michel J Massaad1, Raif S Geha1, Jennifer M Puck14, Paolo Palma15, Caterina Cancrini15, Karin Chen16, Mauno Vihinen17, Frederick W Alt18, Luigi D Notarangelo19. 1. Division of Immunology and Manton Center for Orphan Disease Research, Children's Hospital, Harvard Medical School, Boston, Mass. 2. Division of Immunology and Manton Center for Orphan Disease Research, Children's Hospital, Harvard Medical School, Boston, Mass; Division of Pediatric Allergy/Immunology, Massachusetts General Hospital for Children, Boston, Mass. 3. A. Nocivelli Institute for Molecular Medicine, Pediatric Clinic, University of Brescia, and the Section of Genetics, Department of Pathology Spedali Civili, Brescia, Italy. 4. Department of Paediatric Immunology, Newcastle Upon Tyne Hospital, NHS Foundation Trust, United Kingdom and Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom. 5. Department of Pediatrics, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait. 6. Department of Pediatrics and Department of Microbiology, Infectiology and Immunology, University of Montreal, CHU Sainte-Justine Research Center, Montreal, Quebec, Canada. 7. Division of Hematology/Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 8. Division of Hematology-Oncology, Boston Children's Hospital, Boston, Mass. 9. Divisions of Hematology and Oncology, Indiana University School of Medicine, Indianapolis, Ind. 10. Department of Pediatric Allergy and Immunology, Children's Hospital, Faculty of Medicine, Ain Shams University, Cairo, Egypt. 11. Paediatric Infectious Diseases and Immunodeficiencies Unit, Vall d'Hebron University Hospital, Barcelona, Spain. 12. Division of Allergy and Immunology, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Ill. 13. Immunology Clinic, Levine Children's Hospital, Carolinas Medical Center, Charlotte, NC. 14. Department of Pediatrics, University of California San Francisco and UCSF Benioff Children's Hospital, San Francisco, Calif. 15. DPUO, University Department of Pediatrics, Bambino Gesù Children's Hospital and University of Tor Vergata School of Medicine, Rome, Italy. 16. Division of Allergy, Immunology & Rheumatology, Department of Pediatrics, University of Utah, Salt Lake City, Utah. 17. Department of Experimental Medical Science, Lund University, Lund, Sweden. 18. Howard Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, and the Department of Genetics, Harvard Medical School, Boston, Mass. Electronic address: alt@enders.tch.harvard.edu. 19. Division of Immunology and Manton Center for Orphan Disease Research, Children's Hospital, Harvard Medical School, Boston, Mass. Electronic address: luigi.notarangelo@childrens.harvard.edu.
Abstract
BACKGROUND: The recombination-activating gene (RAG) 1/2 proteins play a critical role in the development of T and B cells by initiating the VDJ recombination process that leads to generation of a broad T-cell receptor (TCR) and B-cell receptor repertoire. Pathogenic mutations in the RAG1/2 genes result in various forms of primary immunodeficiency, ranging from T(-)B(-) severe combined immune deficiency to delayed-onset disease with granuloma formation, autoimmunity, or both. It is not clear what contributes to such heterogeneity of phenotypes. OBJECTIVE: We sought to investigate the molecular basis for phenotypic diversity presented in patients with various RAG1 mutations. METHODS: We have developed a flow cytometry-based assay that allows analysis of RAG recombination activity based on green fluorescent protein expression and have assessed the induction of the Ighc locus rearrangements in mouse Rag1(-/-) pro-B cells reconstituted with wild-type or mutant human RAG1 (hRAG1) using deep sequencing technology. RESULTS: Here we demonstrate correlation between defective recombination activity of hRAG1 mutant proteins and severity of the clinical and immunologic phenotype and provide insights on the molecular mechanisms accounting for such phenotypic diversity. CONCLUSIONS: Using a sensitive assay to measure the RAG1 activity level of 79 mutations in a physiologic setting, we demonstrate correlation between recombination activity of RAG1 mutants and the severity of clinical presentation and show that RAG1 mutants can induce specific abnormalities of the VDJ recombination process.
BACKGROUND: The recombination-activating gene (RAG) 1/2 proteins play a critical role in the development of T and B cells by initiating the VDJ recombination process that leads to generation of a broad T-cell receptor (TCR) and B-cell receptor repertoire. Pathogenic mutations in the RAG1/2 genes result in various forms of primary immunodeficiency, ranging from T(-)B(-) severe combined immune deficiency to delayed-onset disease with granuloma formation, autoimmunity, or both. It is not clear what contributes to such heterogeneity of phenotypes. OBJECTIVE: We sought to investigate the molecular basis for phenotypic diversity presented in patients with various RAG1 mutations. METHODS: We have developed a flow cytometry-based assay that allows analysis of RAG recombination activity based on green fluorescent protein expression and have assessed the induction of the Ighc locus rearrangements in mouse Rag1(-/-) pro-B cells reconstituted with wild-type or mutant human RAG1 (hRAG1) using deep sequencing technology. RESULTS: Here we demonstrate correlation between defective recombination activity of hRAG1 mutant proteins and severity of the clinical and immunologic phenotype and provide insights on the molecular mechanisms accounting for such phenotypic diversity. CONCLUSIONS: Using a sensitive assay to measure the RAG1 activity level of 79 mutations in a physiologic setting, we demonstrate correlation between recombination activity of RAG1 mutants and the severity of clinical presentation and show that RAG1 mutants can induce specific abnormalities of the VDJ recombination process.
Authors: Taco W Kuijpers; Hanna Ijspeert; Ester M M van Leeuwen; Machiel H Jansen; Mette D Hazenberg; Kees C Weijer; Rene A W van Lier; Mirjam van der Burg Journal: Blood Date: 2011-04-18 Impact factor: 22.113
Authors: Lauren A Henderson; Francesco Frugoni; Gregory Hopkins; Helen de Boer; Sung-Yun Pai; Yu Nee Lee; Jolan E Walter; Melissa M Hazen; Luigi D Notarangelo Journal: J Allergy Clin Immunol Date: 2013-07-24 Impact factor: 10.793
Authors: William Giblin; Monalisa Chatterji; Gerwin Westfield; Tehmina Masud; Brian Theisen; Hwei-Ling Cheng; Jeffrey DeVido; Frederick W Alt; David O Ferguson; David G Schatz; JoAnn Sekiguchi Journal: Blood Date: 2009-01-06 Impact factor: 22.113
Authors: A Villa; C Sobacchi; L D Notarangelo; F Bozzi; M Abinun; T G Abrahamsen; P D Arkwright; M Baniyash; E G Brooks; M E Conley; P Cortes; M Duse; A Fasth; A M Filipovich; A J Infante; A Jones; E Mazzolari; S M Muller; S Pasic; G Rechavi; M G Sacco; S Santagata; M L Schroeder; R Seger; D Strina; A Ugazio; J Väliaho; M Vihinen; L B Vogler; H Ochs; P Vezzoni; W Friedrich; K Schwarz Journal: Blood Date: 2001-01-01 Impact factor: 22.113
Authors: Fang Fang Yin; Scott Bailey; C Axel Innis; Mihai Ciubotaru; Satwik Kamtekar; Thomas A Steitz; David G Schatz Journal: Nat Struct Mol Biol Date: 2009-04-26 Impact factor: 15.369
Authors: Xiaomin Yu; Jorge R Almeida; Sam Darko; Mirjam van der Burg; Suk See DeRavin; Harry Malech; Andrew Gennery; Ivan Chinn; Mary Louise Markert; Daniel C Douek; Joshua D Milner Journal: J Allergy Clin Immunol Date: 2014-01-07 Impact factor: 10.793
Authors: Mona Hedayat; Michel J Massaad; Yu Nee Lee; Mary Ellen Conley; Jordan S Orange; Toshiro K Ohsumi; Waleed Al-Herz; Luigi D Notarangelo; Raif S Geha; Janet Chou Journal: J Allergy Clin Immunol Date: 2014-06-27 Impact factor: 10.793
Authors: Jared H Rowe; Brian D Stadinski; Lauren A Henderson; Lisa Ott de Bruin; Ottavia Delmonte; Yu Nee Lee; M Teresa de la Morena; Rakesh K Goyal; Anthony Hayward; Chiung-Hui Huang; Maria Kanariou; Alejandra King; Taco W Kuijpers; Jian Yi Soh; Benedicte Neven; Jolan E Walter; Eric S Huseby; Luigi D Notarangelo Journal: J Allergy Clin Immunol Date: 2017-08-31 Impact factor: 10.793
Authors: Kerstin Felgentreff; Yu Nee Lee; Francesco Frugoni; Likun Du; Mirjam van der Burg; Silvia Giliani; Ilhan Tezcan; Ismail Reisli; Ester Mejstrikova; Jean-Pierre de Villartay; Barry P Sleckman; John Manis; Luigi D Notarangelo Journal: J Allergy Clin Immunol Date: 2015-04-25 Impact factor: 10.793
Authors: Rabab E El Hawary; Safa S Meshaal; Dalia S Abd Elaziz; Marwa A Elsharkawy; Radwa S Alkady; Sohilla Lotfy; Ahmad El-Sheikhah; Amr Hassan; Nermeen M Galal; Jeannette A Boutros; Aisha M Elmarsafy Journal: Mol Diagn Ther Date: 2017-12 Impact factor: 4.074